Y-mAbs Therapeutics, Inc. Retained Earnings
Y-mAbs Therapeutics, Inc. had Retained Earnings of -$495.57 million as of 2025-06-30, per its 10-Q filed 2025-08-08.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2025-08-08
- 2025-06-30: Retained Earnings (Accumulated Deficit) -$495.57M.
- 2025-03-31: Retained Earnings (Accumulated Deficit) -$492.33M.
- 2024-12-31: Retained Earnings (Accumulated Deficit) -$487.14M.
- 2024-09-30: Retained Earnings (Accumulated Deficit) -$480.35M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2025-06-30 | -$495.57M 10-Q · filed 2025-08-08 |
| 2025-03-31 | -$492.33M 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$487.14M 10-Q · filed 2025-08-08 |
| 2024-09-30 | -$480.35M 10-Q · filed 2024-11-08 |
| 2024-06-30 | -$473.35M 10-Q · filed 2024-08-12 |
| 2024-03-31 | -$464.10M 10-Q · filed 2024-05-07 |
| 2023-12-31 | -$457.47M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$456.48M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$448.74M 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$442.43M 10-Q · filed 2023-05-08 |
| 2022-12-31 | -$436.04M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$437.20M 10-Q · filed 2022-11-07 |
| 2022-06-30 | -$409.67M 10-Q · filed 2022-08-08 |
| 2022-03-31 | -$368.54M 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$340.48M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$303.58M 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$274.72M 10-Q · filed 2021-08-09 |
| 2021-03-31 | -$251.79M 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$285.20M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$265.27M 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$232.44M 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$192.04M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$165.86M 10-K · filed 2021-03-01 |
| 2019-09-30 | -$142.73M 10-Q · filed 2019-11-13 |
| 2019-06-30 | -$118.81M 10-Q · filed 2019-08-14 |
| 2019-03-31 | -$100.77M 10-Q · filed 2019-05-10 |
| 2018-12-31 | -$84.83M 10-K · filed 2020-03-12 |
| 2018-09-30 | -$70.78M 10-Q · filed 2018-11-13 |
| 2017-12-31 | -$41.56M 10-K · filed 2019-03-22 |